Form 8-K

8-K — CNS Pharmaceuticals, Inc.

Accession: 0001683168-26-005233

Filed: 2026-07-02

Period: 2026-07-02

CIK: 0001729427

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — cns_8k.htm (Primary)

EX-99.1 — PRESENTATION DATED JULY 2026 (cns_ex9901.htm)

GRAPHIC (image_014.jpg)

GRAPHIC (image_015.jpg)

GRAPHIC (image_016.jpg)

GRAPHIC (image_017.jpg)

GRAPHIC (image_018.jpg)

GRAPHIC (image_019.jpg)

GRAPHIC (image_020.jpg)

GRAPHIC (image_021.jpg)

GRAPHIC (image_022.jpg)

GRAPHIC (image_023.jpg)

GRAPHIC (image_024.jpg)

GRAPHIC (image_025.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: cns_8k.htm · Sequence: 1

8-K

false

0001729427

2026-07-02

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

July 2, 2026

___________________________

CNS Pharmaceuticals, Inc.

(Exact name of registrant as specified in its

charter)

___________________________

Nevada

001-39126

82-2318545

(State or other jurisdiction of

incorporation or organization)

(Commission File Number)

(I.R.S. Employer Identification No.)

2100 West Loop South, Suite 900

Houston, Texas 77027

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including

area code: (800) 946-9185

Not Applicable

(Former Name or Former Address, if Changed

Since Last Report)

___________________________

Check the appropriate

box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following

provisions (see General Instruction A.2. below):

☐ Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth

company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange

Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by

check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section

12(b) of the Act:

Title of each class

Trading Symbols(s)

Name of each exchange on which registered

Common stock, par value $0.001 per share

CNSP

The NASDAQ Stock Market LLC

Item 7.01. Regulation FD Disclosure.

July 2, 2026, CNS Pharmaceuticals, Inc. (the “Company”) posted the investor presentation set forth in Exhibit 99.1 on its

website.

The

information contained in Item 7.01 of this Current Report on Form 8-K is being furnished and shall not be “filed” for the

purpose of the Securities Exchange Act of 1934, as amended (“Exchange Act”), nor shall it be incorporated by reference in

any filing under the Exchange Act or the Securities Act of 1933, as amended (“Securities Act”), unless specifically identified

therein as being incorporated by reference.

Item 9.01. Financial

Statements and Exhibits.

Exhibit No.

Exhibit Description

99.1

Presentation dated July 2026

104

Cover page Interactive Data File (embedded within the Inline XBRL document)

Signature

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

CNS Pharmaceuticals, Inc.

By:

/s/ Rami Levin

Rami Levin

Chief Executive Officer and President

Dated: July 2, 2026

EX-99.1 — PRESENTATION DATED JULY 2026

EX-99.1

Filename: cns_ex9901.htm · Sequence: 2

Exhibit 99.1

June 2026 Investor Presentation

2 This presentation incorporates information from materials filed with the SEC and contains forward - looking statements . All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward - looking statements . The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” and similar expressions are intended to identify forward looking statements . We have based these forward - looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short - term and long - term business operations and objectives, and financial needs . These forward - looking statements are subject to a number of risks, uncertainties and assumptions, including those described in the “Risk Factors” section of our most recent Form 10 - K as updated by any subsequent Form 10 - Q filings . It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward - looking statements we may make . In light of these risks, uncertainties and assumptions, the future events and trends discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward - looking statements . Forward Looking Statements

3 Purpose - Built Executive Team Highly experienced executive team with deep expertise in oncology, neurology and rare disease drug development and public company transformation Rapidly Executing a New Corporate Strategy Refocused the company into high - unmet - need in oncology or neurology markets with strong commercial viability Focused on Value Generation Targeting novel, differentiated assets addressing indications with high unmet needs, efficient development pathways and clear milestones $22.5 Million Financing Enables Strategic Pivot Provides validation to our strategy from leading healthcare investors and will enable us to acquire differentiated, clinical - stage assets with identifiable near - term value - inflection catalysts Formal asset search underway targeting high - value preclinical / clinical - stage programs Focused on established markets with clear regulatory pathways and limited treatment options Legacy programs being positioned for out - licensing to unlock potential non - dilutive upside Lean operating structure designed for capital - efficient development Targeting assets with strong biological rationale, differentiated profiles and near - term catalysts Company Highlights 3

4 The CNS Executive Team Rami Levin, MBA President & CEO 30 years of global leadership experience across oncology, CNS, rare diseases, endocrinology, and cell and gene therapy, with a proven track record of scaling organizations, advancing late - stage clinical programs, and driving transformative value creation. Eric Faulkner, MSc, MBA Chief Technology Officer Over 30 years of global biotechnology leadership across technical operations, CMC, product launch and commercialization, with deep experience advancing programs from development through regulatory approval and market launch. Lynne Kelley, MD, FACS Chief Medical Officer Over 20 years of clinical and regulatory leadership experience, guiding late - stage development programs through IND, NDA and PMA submissions, presenting to FDA advisory committees, and securing key regulatory designations across oncology and medical device platforms. Steve O’Loughlin Chief Financial Officer 20 years of corporate finance, capital markets and business development experience in the biopharmaceutical industry, with a proven track record of executing strategic transactions, securing significant non - dilutive partnerships, and supporting public company growth. Dylan Wenke, MBA Chief Business Officer Corporate development executive with deep experience originating and executing high - value licensing and strategic transactions, supporting portfolio expansion and capital formation in emerging biotech companies.

5 Rapid Execution with Key Building Blocks in Place Appointed CEO, Rami Levin Commenced pipeline analysis Announced new corporate strategy Closed $22.5 million financing Top Performing PIPE for the First Half of 2026 Appointed CFO, CTO, CMO & CBO Accomplished executive team with specific & relevant experience Strategic pivot to be built around innovative assets Targeting high - value indications with unmet needs Committed to data - driven, capital efficient value creation Asset Acquisition Asset Evaluation May March January 2026 Asset Development Positive Market Reaction to Recent Strategic Pivots CNS’s New Focus Capital to Execute Asset Acquisition Strategy Secured 1 1. Based on Management’s Current Expectations

6 Outcome of Comprehensive Strategic Review Independent Analysis Across Clinical, Commercial and Capital Dimensions Underscores Need for a Disciplined Reset Legacy Pipeline Review Strong scientific merit, but GBM focus not aligned with long - term growth strategy Encouraging clinical activity in recurrent GBM supports continued development TPI 287: Advanced through randomized Phase 2 evaluation, generating meaningful data in a historically difficult indication Berubicin: Exploring out - licensing opportunities for legacy assets to advance their development Outcome of Review Defines Strategic Path Forward Executing a disciplined path forward, leveraging newly assembled executive team’s deep expertise across clinical development to identify and advance potential high - value asset Redirect corporate focus toward larger, high - value oncology or neurology markets

7 Disciplined Asset Acquisition Strategy to Unlock Value Clear Selection Criteria Process Capitalizing on Favorable Environment Broad Target Universe Searching Globally • Large Pharma • Biotechnology • Venture - backed assets • Underfunded clinical - stage programs • Shelved/deprioritized assets • Distressed or restructuring • High quality assets facing funding constraints • Strategic reprioritizations creating shelved programs • Increased need and willingness to transact across the sector • Biological rationale • Scientific validation • Regulatory strategy defined • Commercial opportunity • Best - in - Class Potential Focused on Acquiring Assets with a Clear and Actionable Development Pathway in Oncology or Neurology with Value Generating Catalysts Within the Next 12 Months

8 Focusing on Oncology or Neurology Targeting Therapeutic Areas with Proven Investor Interest and Commercial Success, Capitalizing on the Experience of our New Executive Team Oncology Largest and most active sector in biotechnology • Global oncology therapeutics market projected to exceed $400B over the next decade 1 • Oncology represents the largest share of biotech R&D pipeline • Broad target diversity with clearly defined clinical benchmarks for success and accelerated regulatory pathways • Precision medicine enabling differentiated therapies in defined patient populations Neurology Large, growing markets with significant unmet medical need • Global neurological therapeutics market exceeds $138B and continues to expand 2 • Diseases of aging driving increased prevalence of neurodegenerative disease • Advancing biology and regulatory clarity enabling new treatment approaches • Significant commercial portfolio of branded products facing LOE by 2030 1. Nova One Advisor. Oncology Drugs Market Size, Share & Trends Analysis Report. Available at: https://www.novaoneadvisor.com/re por t/oncology - drugs - market 2. Grand View Research. Central Nervous System Therapeutics Market Size, Share & Trends Analysis Report. Available at: https://www.grandviewresearch.com/industry - analysis/central - nervous - system - cns - therapeutic - market

9 Positioned for Rapid Execution Integrating Diligence & Operational Planning Near Term Inflection Catalyst Cohesive Leadership Team Leveraging functional expertise to drive value Biological Risk Mapping Validate scientific rationale and mechanism of action to ensure best - in - class potential CMC & Technical Readiness Evaluate technical operations and established CMC early to remove manufacturing hurdles before acquisition Clinical & Regulatory Mapping Map late - stage development and FDA pathways during diligence to ensure clear clinical benchmarks Strategic Asset Acquisition Compressed Development Cycle Value Inflection Catalyst Execute on underfunded or shelved clinical - stage programs with actionable development pathways Utilize lean operating structures and expert leadership to accelerate program milestones Deliver a meaningful clinical or regulatory milestone within 12 months of acquisition 12 By Month Day 1

10 Why CNSP, Why Now. Unique Opportunity to Participate in a Public Biotech Strategic Pivot New Executive Team with Proven Execution Purpose - built executive team with deep expertise across neurology, oncology and rare disease development Strategic Pivot Underway Comprehensive review defining a disciplined path forward focused on higher - value opportunities Disciplined Asset Acquisition Strategy Targeting large, high - growth markets with structured search underway to identify differentiated asset in oncology or neurology $22.5 Million Financing From leading healthcare investors validates strategic pivot and provides sufficient capital to execute 1 1. Based on Management’s Current Expectations

11 Clean, Shareholder - Aligned Capital Structure May 2026 Private Placement Significantly Enhances Financial Position, Resulting in a Pro Forma Fully Diluted Market Capitalization of ~$50.7 Million Notes Amount Shares As of June 30, 2026¹ 1,461,449 Common stock outstanding $0.001 exercise price; issued in the May 2026 PIPE² 9,143,479 Pre - funded warrants Excludes other outstanding options and warrants¹ 10,604,928 Common + pre - funded warrants As of June 30, 2026 3 ~$50.7 Million Pro Forma Market Cap on a Fully Exercised Basis MAY 2026 PRIVATE PLACEMENT TERMS • 650,000 common shares at $2.30 and 9,143,479 pre - funded warrants at $2.299 — gross proceeds of ~$22.5 million² • Closed May 5, 2026, with participation from ADAR1 Capital, Ikarian Capital, Stonepine Capital Management and Nazare Partners² 1. Per resale registration statement; excludes pre - funded warrants and other exercisable or issuable instruments. Figures are u naudited. 2. Per Company announcements and SEC filings related to the May 2026 private placement 3. Based on closing price of CNSP on June 30, 2026, assuming exercise of all pre - funded warrants, figure is subject to change an d should be confirmed STRUCTURED FOR ALIGNMENT No Debt, Preferred or Convertible Securities Clean capital structure ensures capital to be invested in asset in - licensing and development to enable strategic pivot and value creation Issuance Discipline Restrictions on additional equity issuance post - closing and on variable - rate financings for one - year² Concentration Limits Warrant exercises subject to 4.99% / 9.99% beneficial ownership caps²

Investor Relations: JTC Team cnsp@jtcir.com

GRAPHIC

Filename: image_014.jpg · Sequence: 6

Binary file (243261 bytes)

Download image_014.jpg

GRAPHIC

Filename: image_015.jpg · Sequence: 7

Binary file (210710 bytes)

Download image_015.jpg

GRAPHIC

Filename: image_016.jpg · Sequence: 8

Binary file (195267 bytes)

Download image_016.jpg

GRAPHIC

Filename: image_017.jpg · Sequence: 9

Binary file (165709 bytes)

Download image_017.jpg

GRAPHIC

Filename: image_018.jpg · Sequence: 10

Binary file (194714 bytes)

Download image_018.jpg

GRAPHIC

Filename: image_019.jpg · Sequence: 11

Binary file (181429 bytes)

Download image_019.jpg

GRAPHIC

Filename: image_020.jpg · Sequence: 12

Binary file (228973 bytes)

Download image_020.jpg

GRAPHIC

Filename: image_021.jpg · Sequence: 13

Binary file (187172 bytes)

Download image_021.jpg

GRAPHIC

Filename: image_022.jpg · Sequence: 14

Binary file (146617 bytes)

Download image_022.jpg

GRAPHIC

Filename: image_023.jpg · Sequence: 15

Binary file (186395 bytes)

Download image_023.jpg

GRAPHIC

Filename: image_024.jpg · Sequence: 16

Binary file (56097 bytes)

Download image_024.jpg

GRAPHIC

Filename: image_025.jpg · Sequence: 17

Binary file (35302 bytes)

Download image_025.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 19

v3.26.1

Cover

Jul. 02, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jul. 02, 2026

Entity File Number

001-39126

Entity Registrant Name

CNS Pharmaceuticals, Inc.

Entity Central Index Key

0001729427

Entity Tax Identification Number

82-2318545

Entity Incorporation, State or Country Code

Entity Address, Address Line One

2100 West Loop South

Entity Address, Address Line Two

Suite 900

Entity Address, City or Town

Houston

Entity Address, State or Province

Entity Address, Postal Zip Code

77027

City Area Code

(800)

Local Phone Number

946-9185

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common stock, par value $0.001 per share

Trading Symbol

CNSP

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

Entity Information, Former Legal or Registered Name

Not Applicable

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

Former Legal or Registered Name of an entity

+ References

No definition available.

+ Details

Name:

dei_EntityInformationFormerLegalOrRegisteredName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration